Concept information
Preferred term
Tumor observable (observable entity)
Type
-
http://www.irandoc.ac.ir/onto/irandoc-meta/Concept
Broader concept
Narrower concepts
- Additional pathologic finding in tumor specimen (observable entity)
- Clockface position of neoplasm (observable entity)
- Degree of pigmentation of tumor (observable entity)
- Distance of tumor from anal verge (observable entity)
- Dukes stage (observable entity)
- Edition of American Joint Commission on Cancer, Cancer Staging Manual used for TNM staging (observable entity)
- FIGO stage for gynecological malignancy (observable entity)
- Functional status of pancreatic endocrine tumor (observable entity)
- Generic tumour extent
- Histologic feature of tumor (observable entity)
- Intergroup rhabdomyosarcoma study post-surgical clinical group (observable entity)
- International neuroblastoma pathology classification (observable entity)
- Linear extent of involvement of carcinoma (observable entity)
- Location of malignant melanoma in specimen with involved deep margin (observable entity)
- Location of malignant melanoma in specimen with uninvolved lateral margin (observable entity)
- Location of melanoma in situ in specimen with uninvolved lateral margin (observable entity)
- Location of tumor in relation to closest lateral margin (observable entity)
- Location of tumor within eye (observable entity)
- Location of tumor within lateral margin (observable entity)
- Lymphoma extent of involvement (observable entity)
- Modified Dukes stage
- National Wilms Tumor Study Group Stage (observable entity)
- Number of positive prostatic tissue chips obtained by resection (observable entity)
- Number of tissue chips positive for carcinoma (observable entity)
- Organ AND/OR tissue involved by tumor (observable entity)
- Pathologic stage (observable entity)
- Percentage of sarcomatoid element in tumor (observable entity)
- Percentage span of neoplasm consisting of epithelium (observable entity)
- Percentage span of neoplasm consisting of stroma (observable entity)
- Proportion of specimen involved by tumor (observable entity)
- Region of fallopian tube involved by tumor (observable entity)
- Residual cancer burden index (observable entity)
- Residual tumor
- Serum tumor marker category (observable entity)
- Serum tumor marker status values
- Site involved by extension of neoplasm (observable entity)
- Site of invasive ovarian tumor omental implant (observable entity)
- Site of largest single mass (observable entity)
- Site of non-invasive (desmoplastic) ovarian tumor omental implant (observable entity)
- Site of non-invasive (epithelial) ovarian tumor omental implant (observable entity)
- Size of tumor
- Stage of tumor involvement of non-regional lymph nodes (observable entity)
- Status of adrenal gland involvement by tumor (observable entity)
- Status of correlation between radiographic image and pathologic finding (observable entity)
- Status of distant metastasis (observable entity)
- Status of estrogen receptors of neoplasm (observable entity)
- Status of intratumoral/peritumoral lymphocyte response (observable entity)
- Status of invasive ovarian tumor omental implants (observable entity)
- Status of non-invasive (desmoplastic) ovarian tumor omental implants (observable entity)
- Status of non-invasive (epithelial) ovarian tumor omental implants (observable entity)
- Status of ovarian tumor omental implants (observable entity)
- Status of progesterone receptors of neoplasm (observable entity)
- Status of regression of tumor (observable entity)
- Status of renal sinus involvement by tumor (observable entity)
- Status of residual neoplasm (observable entity)
- Status of specimen involvement by macroscopic tumor (observable entity)
- Status of specimen involvement by matted nodes (observable entity)
- Status of specimen involvement by multifocal invasion (observable entity)
- Status of specimen involvement by satellite nodule(s) (observable entity)
- Status of tumor infiltration by lymphocytes (observable entity)
- Status of tumor involvement by anaplasia (observable entity)
- Status of tumor involvement by necrosis (observable entity)
- Status of tumor metastasis to non-regional lymph nodes (observable entity)
- Status of tumor metastasis to regional lymph nodes (observable entity)
- TNM tumor observable (observable entity)
- Tumor border behavior
- Tumor configuration (observable entity)
- Tumor extent of invasion, macroscopic (observable entity)
- Tumor extent of invasion (observable entity)
- Tumor focality (observable entity)
- Tumor immunophenotyping status (observable entity)
- Tumor location after sectioning (observable entity)
- Tumor nodule site (observable entity)
- Tumor pigmentation (observable entity)
- Tumor quantitation (observable entity)
- Tumor site (observable entity)
- Tumor stage (observable entity)
- Tumor viability (observable entity)
- Tumor volume
- Tumor weight (observable entity)
- Type of polyp from which malignant neoplasm originated (observable entity)
- Type of study performed on tumor specimen (observable entity)
- WHO tumor classification cannot be determined (observable entity)
- WHO tumor classification (observable entity)
Inheres in
In other languages
URI
http://www.irandoc.acir/onto/irandoc/395531003
{{label}}
{{#each values }} {{! loop through ConceptPropertyValue objects }}
{{#if prefLabel }}
{{/if}}
{{/each}}
{{#if notation }}{{ notation }} {{/if}}{{ prefLabel }}
{{#ifDifferentLabelLang lang }} ({{ lang }}){{/ifDifferentLabelLang}}
{{#if vocabName }}
{{ vocabName }}
{{/if}}